Two drugs with paradoxical effects on liver regeneration through antiangiogenesis and antifibrosis: Losartan and Spironolactone: A pharmacologic dilemma on hepatocyte proliferation

Parlakgumus A., Colakoglu T., Kayaselcuk F., Colakoglu S., Ezer A., Caliskan K., ...More

JOURNAL OF SURGICAL RESEARCH, vol.179, no.1, pp.60-65, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 179 Issue: 1
  • Publication Date: 2013
  • Doi Number: 10.1016/j.jss.2012.08.046
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.60-65
  • Hacettepe University Affiliated: Yes


Background: There is a strong relationship between liver regeneration and angiogenesis and fibrosis. It is known that Spironolactone, an aldosterone antagonist, acting on rennin ealdosterone axis, and Losartan, an angiotensin II type I antagonist, have both antifibrotic and antiangiogenic effects. Theoretically, the end result of these mechanisms with contradictory influences on liver regeneration is not known well. In this study, we aimed to reveal the effects on liver regeneration of administration of Spironolactone and Losartan, having contradicting effects on regeneration through antiangiogenesis and antifibrosis.